» Articles » PMID: 38147180

Stability of Peri-implantitis Surgical Reconstructive Therapy-a (> 2 years) Follow-up of a Randomized Clinical Trial

Overview
Specialty Dentistry
Date 2023 Dec 26
PMID 38147180
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: This follow-up study aimed to report the 24- and 30-month outcomes of a cohort previously enrolled in a randomized clinical trial on surgical reconstructive treatment of peri-implantitis.

Methods: Twenty-four patients were diagnosed with peri-implantitis and treated with surgical reconstructive therapy with or without the adjunctive use of Er:YAG laser. Within-group and between-group comparisons were tested with mixed model with repeated measures.

Results: Regarding peri-implant pocket depth (PPD) reduction (control vs. laser test group) between 6 months (- 1.85 vs. - 2.65 mm) and 30 months (- 1.84 vs. - 3.04 mm), the laser group showed statistically significant changes but not the control group. In terms of radiographic marginal bone loss (RMBL) at 6 months (- 1.1 vs. - 1.46 mm) to 24 months (- 1.96 vs. - 2.82 mm), both groups showed statistical difference compared to baseline. The six explanted implants all were featured by severe peri-implantitis and mostly with no or limited keratinized tissue (< 2 mm) at baseline and membrane exposure after surgery. Among the 15 retained cases, eight cases achieved more than 50% peri-implant bone level gain.

Conclusions: Within the limitation and follow-up time frame of this trial, the outcome of the surgical reconstructive therapy sustained or improved in most of the cases. However, 25% of the implants with severe peri-implantitis failed 2 years after the surgical reconstructive therapy. The use of Er:YAG laser favors PPD reduction in the longer term up to 30 months.

Clinical Relevance: Longer-term follow-up on reconstructive therapy of peri-implantitis revealed sustained or improved stability in certain cases, but the survival of implants with severe peri-implantitis has its limitation, especially when there is limited keratinized tissue (< 2 mm or no KT).

Trial Registration: Clinical Trials Registration Number: NCT03127228 and HUM00160290.

Citing Articles

Advancing Peri-Implantitis Treatment: A Scoping Review of Breakthroughs in Implantoplasty and Er:YAG Laser Therapies.

Mojaver S, Fiorellini J, Sarmiento H Clin Exp Dent Res. 2025; 11(1):e70104.

PMID: 40071719 PMC: 11898008. DOI: 10.1002/cre2.70104.

References
1.
Derks J, Schaller D, Hakansson J, Wennstrom J, Tomasi C, Berglundh T . Effectiveness of Implant Therapy Analyzed in a Swedish Population: Prevalence of Peri-implantitis. J Dent Res. 2015; 95(1):43-9. DOI: 10.1177/0022034515608832. View

2.
Chan H, Lin G, Suarez F, MacEachern M, Wang H . Surgical management of peri-implantitis: a systematic review and meta-analysis of treatment outcomes. J Periodontol. 2013; 85(8):1027-41. DOI: 10.1902/jop.2013.130563. View

3.
Wang C, Renvert S, Wang H . Nonsurgical Treatment of Periimplantitis. Implant Dent. 2019; 28(2):155-160. DOI: 10.1097/ID.0000000000000846. View

4.
Renvert S, Lindahl C, Persson G . Occurrence of cases with peri-implant mucositis or peri-implantitis in a 21-26 years follow-up study. J Clin Periodontol. 2017; 45(2):233-240. DOI: 10.1111/jcpe.12822. View

5.
Carcuac O, Derks J, Abrahamsson I, Wennstrom J, Berglundh T . Risk for recurrence of disease following surgical therapy of peri-implantitis-A prospective longitudinal study. Clin Oral Implants Res. 2020; 31(11):1072-1077. DOI: 10.1111/clr.13653. View